drugset / Trial / NCT01112982

An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.

NCT01112982

Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to show that patients with gout suffer from chronic inflammation of their joints, observable by MRI, even in the absence of symptomatic gouty attacks. Secondary end-points of this study will include analyzing the effects of uric acid-lowering therapy (specifically with the FDA approved medication Febuxostat) in a subgroup of patients, checking for the presence of inflammatory markers to see if there is any correlation with the proposed chronic inflammation, and evaluating for other characteristic findings of gout on MRI.

Timeline

Start
2010-05
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Febuxostat Small molecule 40 mg
Subject Febuxostat Small molecule 80 mg
Background Colchicine Small molecule 0.6 mg Oral

Indications